EA200801461A1 - Агенты, связывающиеся с ядерными рецепторами - Google Patents

Агенты, связывающиеся с ядерными рецепторами

Info

Publication number
EA200801461A1
EA200801461A1 EA200801461A EA200801461A EA200801461A1 EA 200801461 A1 EA200801461 A1 EA 200801461A1 EA 200801461 A EA200801461 A EA 200801461A EA 200801461 A EA200801461 A EA 200801461A EA 200801461 A1 EA200801461 A1 EA 200801461A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
nuclear receptors
cancer
diseases
Prior art date
Application number
EA200801461A
Other languages
English (en)
Other versions
EA018066B1 (ru
Inventor
Джеймс Т. Долтон
Кристина Баррет
Яли Хе
Сынг-Соо Хонг
Дуэйн Д. Миллер
Майкл Л. Молер
Рамеш Нараянан
Чжонгчжи Ву
Original Assignee
Джи Ти Икс, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи Ти Икс, ИНК. filed Critical Джи Ти Икс, ИНК.
Publication of EA200801461A1 publication Critical patent/EA200801461A1/ru
Publication of EA018066B1 publication Critical patent/EA018066B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)

Abstract

Настоящее изобретение касается нового класса селективных модуляторов рецепторов эстрогенов (selective estrogen receptor modulators, SERMs). Соединения SERM пригодны для применения для предотвращения и/или лечения различных заболеваний и состояний, включая предотвращение и лечение рака, такого как рак простаты и рак груди, остеопороза, гормонозависимых заболеваний, приливов жара или вазомоторных симптомов, неврологических заболеваний, сердечно-сосудистого заболевания и ожирения.
EA200801461A 2005-11-28 2006-11-28 Агент, связывающийся с ядерными рецепторами EA018066B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73989805P 2005-11-28 2005-11-28
PCT/US2006/045451 WO2007062230A2 (en) 2005-11-28 2006-11-28 Nuclear receptor binding agents

Publications (2)

Publication Number Publication Date
EA200801461A1 true EA200801461A1 (ru) 2008-12-30
EA018066B1 EA018066B1 (ru) 2013-05-30

Family

ID=38067963

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200801461A EA018066B1 (ru) 2005-11-28 2006-11-28 Агент, связывающийся с ядерными рецепторами
EA201500845A EA201500845A1 (ru) 2005-11-28 2006-11-28 Агенты, связывающиеся с ядерными рецепторами
EA201201021A EA023472B1 (ru) 2005-11-28 2006-11-28 Агенты, связывающиеся с ядерными рецепторами

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201500845A EA201500845A1 (ru) 2005-11-28 2006-11-28 Агенты, связывающиеся с ядерными рецепторами
EA201201021A EA023472B1 (ru) 2005-11-28 2006-11-28 Агенты, связывающиеся с ядерными рецепторами

Country Status (10)

Country Link
US (2) US20070135407A1 (ru)
EP (2) EP2455362A1 (ru)
CN (3) CN102702013B (ru)
AU (1) AU2006318400C1 (ru)
BR (1) BRPI0620520A2 (ru)
CA (2) CA2824517A1 (ru)
EA (3) EA018066B1 (ru)
IL (2) IL191803A (ru)
MX (1) MX2008006885A (ru)
WO (1) WO2007062230A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CA2640608A1 (en) * 2006-02-01 2007-08-09 Merck & Co., Inc. Potassium channel inhibitors
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CA2753436C (en) * 2009-02-23 2016-05-24 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
CN102617480A (zh) * 2011-01-30 2012-08-01 中国人民解放军军事医学科学院毒物药物研究所 二-(杂)芳基取代的叔胺类化合物及其制备方法和抗肿瘤应用
CN103957706A (zh) * 2011-08-23 2014-07-30 Gtx公司 雌激素受体配体以及其使用方法
WO2013064206A1 (de) 2011-11-01 2013-05-10 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung
EP2822556A1 (en) * 2012-03-07 2015-01-14 Ligand Pharmaceuticals Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
AU2013203600C1 (en) 2012-07-13 2016-11-24 University Of Tennessee Research Foundation A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
RU2691652C2 (ru) * 2014-10-16 2019-06-17 ДжиТиИкс, ИНК. Способы лечения урологических нарушений с применением селективных модуляторов андрогеновых рецепторов
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2023137406A1 (en) * 2022-01-12 2023-07-20 Shenzhen Ionova Life Science Co., Ltd. Heteroaryl compounds as hpk1 inhibitors and methods of using same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE269213C (ru) *
US3413339A (en) * 1964-06-18 1968-11-26 Parke Davis & Co Amine compounds and methods for their production
US3960886A (en) * 1968-07-03 1976-06-01 Sterling Drug Inc. Substituted N-arylanilines
US3625972A (en) * 1968-07-03 1971-12-07 Sterling Drug Inc N-phenylbenzanilides
US3838131A (en) * 1972-04-03 1974-09-24 Pfizer Di(dialkylamino alkoxy)phenanthridines as antiviral agents
US3838134A (en) * 1972-04-03 1974-09-24 G Gauthier Phenanthridinones as antiviral agents
US4373017A (en) * 1980-03-05 1983-02-08 Konishiroku Photo Industry Co., Ltd. Photosensitive compound and photosensitive material containing it
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
GB9604577D0 (en) * 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
BR9708230A (pt) * 1996-03-20 2000-01-04 Harvard College Compostos de triaril metano, composição farmacêutica, e métodos de inibição do transporte de potássio ativado por cálcio de uma célula, para reduzir a desidrataçào de eritrócito falciforme e/ou retaradar a ocorrência de afoiçamento ou deformação de eritrócitos, e tratamento ou prevenção de doença, de inibição da proliferação celular em mamìferos, e de tratamento ou prevenção de uma desordem.
US20020156301A1 (en) * 1997-06-17 2002-10-24 Sumitomo Chemical Co., Ltd. Triphenylmethane derivatives and use thereof
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6166013A (en) * 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
AU5467699A (en) * 1998-08-07 2000-02-28 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
AU4128800A (en) * 1999-04-16 2000-11-02 Astrazeneca Ab Estrogen receptor-beta ligands
JP4320089B2 (ja) * 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
KR20030014407A (ko) * 2000-06-28 2003-02-17 브리스톨-마이어스스퀴브컴파니 융합 고리형 핵 호르몬 수용체 기능 조절체
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
KR20030093240A (ko) * 2001-03-16 2003-12-06 이데미쓰 고산 가부시키가이샤 방향족 아미노 화합물의 제조방법
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
CA2468719C (en) * 2001-11-29 2011-05-24 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
AU2003277478B2 (en) * 2002-11-08 2007-09-20 Snaptrack, Inc. A method, a system and a terminal for realizing presenting information interaction of the wireless LAN users
JP3768196B2 (ja) * 2003-02-10 2006-04-19 出光興産株式会社 芳香族ジアミン誘導体の製造方法
US7601739B2 (en) * 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
CA2658096A1 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof

Also Published As

Publication number Publication date
WO2007062230A2 (en) 2007-05-31
CA2631331C (en) 2016-08-09
CN102702013B (zh) 2016-02-10
CN102351732B (zh) 2014-10-29
MX2008006885A (es) 2008-10-20
EP1954670A4 (en) 2011-04-27
US20090062341A1 (en) 2009-03-05
CN102351732A (zh) 2012-02-15
EA023472B1 (ru) 2016-06-30
US20070135407A1 (en) 2007-06-14
IL191803A0 (en) 2008-12-29
CN102702013A (zh) 2012-10-03
WO2007062230A3 (en) 2007-09-20
AU2006318400C1 (en) 2013-01-17
CA2631331A1 (en) 2007-05-31
AU2006318400A1 (en) 2007-05-31
IL219590A (en) 2015-03-31
IL191803A (en) 2014-03-31
IL219590A0 (en) 2012-06-28
EP1954670A2 (en) 2008-08-13
CA2824517A1 (en) 2007-05-31
AU2006318400B2 (en) 2012-04-05
BRPI0620520A2 (pt) 2011-11-16
EA201500845A1 (ru) 2016-04-29
EA201201021A1 (ru) 2013-01-30
CN101336227A (zh) 2008-12-31
EP2455362A1 (en) 2012-05-23
EA018066B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
EA200801461A1 (ru) Агенты, связывающиеся с ядерными рецепторами
EA200970707A1 (ru) Вещества, связывающие ядерные рецепторы
UY39124A (es) Anticuerpo aislado o fragmento de éste que enlazan beta-klotho, receptores fgf y complejos de los mismos
UY32996A (es) Antagonistas del receptor crth2 basados en indol
SV2002000357A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo ref pc10748amag/bb
EA201200016A1 (ru) Лечение приливов, вазомоторных симптомов и ночной потливости с помощью предшественников половых стероидов в комбинации с избирательными (селективными) модуляторами эстрогеновых рецепторов
MX2009000714A (es) Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
ATE524170T1 (de) Östrogenrezeptor modulatoren
HK1169321A1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
WO2009129260A3 (en) Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
ATE556071T1 (de) Kappa-opioidrezeptor-liganden
CL2012003648A1 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos, moduladores selectivos del receptor de estrogeno (serm); composicion farmaceutica; y uso para tratar y/o prevenir enfermedades cardiovasculares, hiperlipidemia, osteoporosis, alzheimer, endometriosis, tumores hormonodependientes, infertilidad, entre otras.
TW200738732A (en) Thiophenyl and pyrrolyl azepines as serotonin 5-HT2C receptor ligands and uses thereof
NZ585704A (en) Modulators of cannabinoid receptor CB1 for treating obesity
ECSP078043A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
EP1940407A4 (en) N- (4-OXO-3,4-DIHYDROCHINAZOLIN-2-YL) BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS
UY29625A1 (es) Uso de moduladores no esteroides de receptores de progesterona
EA201100226A1 (ru) Производные эстратриена, содержащие гетероциклические биоизостеры для фенольного а-кольца
PA8637801A1 (es) Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
CR9598A (es) Moduladores no esteroides de receptor de progesterona
EA201591199A1 (ru) Бензазепины в качестве лигандов серотониновых 5-ht-рецепторов и их применение
EA200702332A1 (ru) Пролекарства n-тиазол-2-илбензамидных производных
ATE380048T1 (de) Behandlung der männlichen sexuellen dysfunktion
SE0401790D0 (sv) Tamoxifen response in pre- and postmenopausal breast cancer patients

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU